Annual Revenue
N/A
31 December 2023
Summary:
Inhibikase Therapeutics annual revenue is not available.IKT Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
N/A
30 September 2024
Summary:
Inhibikase Therapeutics quarterly revenue is not available.IKT Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
N/A
30 September 2024
Summary:
Inhibikase Therapeutics TTM revenue is not available.IKT TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
IKT Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time |
Inhibikase Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $328.50 K(-75.9%) | $3.27 M(+9.8%) |
| June 2021 | - | $1.36 M(-3.1%) | $2.98 M(+62.3%) |
| Mar 2021 | - | $1.41 M(+725.8%) | $1.83 M(+162.7%) |
| Dec 2020 | $698.50 K | $170.40 K(+352.0%) | $698.50 K(-9.1%) |
| Sept 2020 | - | $37.70 K(-82.8%) | $768.40 K(-10.1%) |
| June 2020 | - | $219.60 K(-18.9%) | $855.10 K(+6.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $270.80 K(+12.7%) | $802.40 K(-28.5%) |
| Dec 2019 | $1.12 M(-72.2%) | $240.30 K(+93.2%) | $1.12 M(+27.2%) |
| Sept 2019 | - | $124.40 K(-25.5%) | $882.40 K(+16.4%) |
| June 2019 | - | $166.90 K(-71.8%) | $758.00 K(+28.2%) |
| Mar 2019 | - | $591.10 K | $591.10 K |
| Dec 2018 | $4.04 M | - | - |
FAQ
- What is the all time high annual revenue for Inhibikase Therapeutics?
- What is the all time high quarterly revenue for Inhibikase Therapeutics?
- What is the all time high TTM revenue for Inhibikase Therapeutics?
What is the all time high annual revenue for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual revenue is $4.04 M
What is the all time high quarterly revenue for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly revenue is $1.41 M
What is the all time high TTM revenue for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM revenue is $3.27 M